07:00 , Jul 16, 2015 |  BC Innovations  |  Translation in Brief

A Sweet Marker for Tregs

Researchers from the Institut National de la Santé et de la Recherche Médicale (INSERM) hope their study published in PNAS last month, which identifies a new sugar-based marker for functional human regulatory T cells (Tregs),...
08:00 , Jan 29, 2015 |  BC Innovations  |  Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

General Electric sales and marketing update

General Electric's Clarient Diagnostic Services Inc. company launched the Hodgkin Lymphoma Profile by MultiOmyx test to aid in the diagnosis of CD30-positive lymphoma with difficult morphology or otherwise insufficient tissue. The test uses Clarient's MultiOmyx...
07:00 , May 2, 2013 |  BC Innovations  |  Tools & Techniques

CTCs gain character(ization)

Despite the recent shuttering of circulating tumor cell diagnostic company On-Q-ity Inc. , researchers at Massachusetts General Hospital think there is still reason to innovate in the space. The group has developed a microfluidic platform...
07:00 , Sep 8, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms In vitro generation of cancer stem cells (CSCs) and selection based on fucosyltransferase 4 a1,3-fucosyltransferase myeloid-specific (FUT4; CD15; SSEA-1) Differentiation of CSCs from somatic cells...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Purified population of early cardiovascular progenitor cells A purified population of cardiovascular progenitor cells could help treat myocardial infarction (MI) and other cardiovascular diseases. Bone...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Clinical News

NeutroSpec regulatory update

PTN and partner TYC withdrew their NeutroSpec imaging agent from the market at FDA's request. The decision comes three weeks after the companies issued a "Dear Healthcare Provider" letter for the product to warn of...
03:20 , Dec 20, 2005 |  BC Extra  |  Company News

Palatin withdraws NeutroSpec

Palatin (PTN) and partner Tyco (TYC) withdrew their NeutroSpec imaging agent from the market at FDA's request. The decision comes three weeks after the companies issued a "Dear Healthcare Provider" letter for the product to...
08:00 , Dec 12, 2005 |  BC Week In Review  |  Clinical News

NeutroSpec regulatory update

PTN issued a "Dear Healthcare Provider" letter to warn of serious and life-threatening cardiopulmonary events, including 2 deaths attributed to cardiopulmonary failure within 30 minutes of injection. Additional cases of serious cardiopulmonary events including cardiac...
08:00 , Jan 31, 2005 |  BC Week In Review  |  Clinical News

NeutroSpec regulatory update

PTN said the Centers for Medicare & Medicaid Services (CMS) issued a temporary reimbursement code for NeutroSpec. Medicare will reimburse the use of NeutroSpec for infection imaging in an outpatient setting. The radiolabeled monoclonal antibody...